Gensight Biologics SA SIGHT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €0.41
- Day Range
- €0.38–0.41
- 52-Week Range
- €0.30–1.15
- Bid/Ask
- €0.38 / €0.40
- Market Cap
- €30.82 Mil
- Volume/Avg
- 83,796 / 154,227
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 15.64
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group's focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 46
Valuation
|
Metric
|
SIGHT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 15.64 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SIGHT
|
|---|---|
Quick Ratio | 0.20 |
Current Ratio | 0.48 |
Interest Coverage | −8.43 |
Quick Ratio
SIGHT
Profitability
|
Metric
|
SIGHT
|
|---|---|
Return on Assets (Normalized) | −188.06% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
SIGHT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xgxzptynx | Xkwks | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rzfynhtl | Hjzdqm | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dtldytn | Nzchrr | $98.3 Bil | |
MRNA
| Moderna Inc | Djzrdfdgm | Vprg | $42.7 Bil | |
ARGX
| argenx SE ADR | Sshnkcfl | Fmwh | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Wpbdhnld | Nlg | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tpvylkl | Ksbtkq | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qzghqjjg | Nhtgprq | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mlgdvtyvv | Gxrlyv | $12.7 Bil | |
INCY
| Incyte Corp | Shmjsjzrk | Tptvtd | $11.8 Bil |